SCHEMBL5286331

SCHEMBL5286331

COC(=O)CNS(=O)(=O)Cc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 2/20 0.55
MMP8 P22894 2/20 0.55
MMP13 P45452 2/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
MMP2 P08253 1/20 0.55
MMP9 P14780 1/20 0.55
HPGD P15428 3/20 0.51
ALDH1A1 P00352 3/20 0.51
KDM4E B2RXH2 1/20 0.51
NPC1 O15118 1/20 0.51
GAA P10253 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
CA12 O43570 1/20 0.51
CA7 P43166 1/20 0.51
CA9 Q16790 1/20 0.51
CA14 Q9ULX7 1/20 0.51
F2 P00734 1/20 0.47
PRSS1 P07477 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15145818 0.83 ALDH1A1 (0.54) MMP1MMP8MMP13CA1CA2
SCHEMBL5281032 0.82 MMP8 (0.62) MMP1MMP8MMP13CA1CA2
SCHEMBL18109149 0.80 CA12 (0.65) CA1CA2HPGDALDH1A1KDM4E
SCHEMBL8657587 0.79 MMP8 (0.51) MMP1MMP8MMP13CA1CA2
SCHEMBL2895067 0.79 MMP1 (0.58) MMP1MMP8MMP13CA1CA2
SCHEMBL7200212 0.77 CA2 (0.67) MMP1MMP8MMP13CA1CA2
SCHEMBL830997 0.77 SMN1; SMN2 (0.54) MMP1MMP8MMP13CA1CA2
SCHEMBL3239227 0.77 ALDH1A1 (0.71) MMP1MMP8MMP13MMP2MMP9
SCHEMBL5320468 0.77 MMP1 (0.56) MMP1MMP8MMP13CA1CA2
SCHEMBL4069328 0.76 LMNA (0.53) CA1CA2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 MMP1 3485/4885MMP8 387/4885MMP13 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.